Strongbridge Biopharma plc (SBBP):企業の財務・戦略的SWOT分析

◆英語タイトル:Strongbridge Biopharma plc (SBBP) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH132607FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Strongbridge Biopharma plc (Strongbridge) formerly Cortendo Plc, is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product KEVEYIS (dichlorphenamide) is indicated for the treatment of hypokalemic, hyperkalemic, and related variants of primary periodic paralysis, a genetic neuromuscular disorder. Its KEVEYIS holds orphan drug designation in the US. Strongbridge’s pipeline products include COR-003 (levoketoconazole) a cortisol synthesis inhibitor for the treatment of endogenous Cushing’s syndrome; and COR-005 a novel somatostatin analog for the treatment of acromegaly with potential use in Cushing’s syndrome and neuroendocrine tumors. The company also provides building franchise around rare endocrine disorders including product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly. Strongbridge is headquartered in Trevose, Pennsylvania, the US.

Strongbridge Biopharma plc Key Recent Developments

Mar 15,2021: Strongbridge Biopharma plc to Present at Oppenheimer’s 31st Annual Healthcare Conference
Mar 03,2021: Strongbridge Biopharma reports fourth quarter and full-year 2020 financial results and provides corporate update
Feb 25,2021: Strongbridge Biopharma plc to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call on March 3, 2021

This comprehensive SWOT profile of Strongbridge Biopharma plc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Strongbridge Biopharma plc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Strongbridge Biopharma plc – Key Information
Strongbridge Biopharma plc – Overview
Strongbridge Biopharma plc – Key Employees
Strongbridge Biopharma plc – Key Employee Biographies
Strongbridge Biopharma plc – Key Operational Heads
Strongbridge Biopharma plc – Major Products and Services
Strongbridge Biopharma plc – History
Strongbridge Biopharma plc – Company Statement
Strongbridge Biopharma plc – Locations And Subsidiaries
Strongbridge Biopharma plc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Strongbridge Biopharma plc – Business Description
Strongbridge Biopharma plc – Corporate Strategy
Strongbridge Biopharma plc – SWOT Analysis
SWOT Analysis – Overview
Strongbridge Biopharma plc – Strengths
Strongbridge Biopharma plc – Weaknesses
Strongbridge Biopharma plc – Opportunities
Strongbridge Biopharma plc – Threats
Strongbridge Biopharma plc – Key Competitors

Section 3 – Company Financial Performance Charts

Strongbridge Biopharma plc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Strongbridge Biopharma plc, Key Information
Strongbridge Biopharma plc, Key Ratios
Strongbridge Biopharma plc, Share Data
Strongbridge Biopharma plc, Major Products and Services
Strongbridge Biopharma plc, History
Strongbridge Biopharma plc, Key Employees
Strongbridge Biopharma plc, Key Employee Biographies
Strongbridge Biopharma plc, Key Operational Heads
Strongbridge Biopharma plc, Other Locations
Strongbridge Biopharma plc, Subsidiaries

Strongbridge Biopharma plc, Key Competitors
Strongbridge Biopharma plc, SWOT Analysis
Strongbridge Biopharma plc, Ratios based on current share price
Strongbridge Biopharma plc, Annual Ratios
Strongbridge Biopharma plc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Strongbridge Biopharma plc (SBBP):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Elektrizitatswerk der Stadt Zurich:電力:M&Aディール及び事業提携情報
    Summary Elektrizitatswerk der Stadt Zurich (EWZ) is an alternative energy company that offers power and energy network services. The company’s services include power and energy supplying and distribution, contact and advice, fault messages, invoice and payment, online consulting and document center …
  • ERHC Energy Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary ERHC Energy Inc (ERHC Energy) is an exploration and production company that explores oil and gas assets. The company possesses deep water oil and gas exploration and production interests in the Gulf of Guinea and onshore interests in Republic of Chad and Republic of Kenya. It holds interests …
  • Sui Northern Gas Pipelines Ltd (SNGP):企業の財務・戦略的SWOT分析
    Sui Northern Gas Pipelines Ltd (SNGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Hosken Consolidated Investments Ltd (HCI):企業の財務・戦略的SWOT分析
    Hosken Consolidated Investments Ltd (HCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Petrolina (Holdings) Public Ltd (PHL):企業の財務・戦略的SWOT分析
    Petrolina (Holdings) Public Ltd (PHL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Saniona AB (SANION):企業の財務・戦略的SWOT分析
    Summary Saniona AB (Saniona) formerly Aniona, is a research and development company that develops drugs for central nervous system diseases, autoimmune diseases, metabolic diseases and pain management. The company’s pipeline products include tesofensine, a triple monoamine reuptake inhibitor, which …
  • MDU Resources Group, Inc.:企業の戦略・SWOT・財務分析
    MDU Resources Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary MDU Resources Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Primearth EV Energy Co Ltd:企業の戦略的SWOT分析
    Primearth EV Energy Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Genuine Parts Company:戦略・SWOT・企業財務分析
    Genuine Parts Company - Strategy, SWOT and Corporate Finance Report Summary Genuine Parts Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Hanwha Techwin Co Ltd:企業の戦略・SWOT・財務情報
    Hanwha Techwin Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Hanwha Techwin Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • ResMed Inc. (RMD)-医療機器分野:企業M&A・提携分析
    Summary ResMed Inc. (ResMed) develops, manufactures and distributes medical equipment for the diagnosis, treatment and management respiratory disorders such as sleep-disordered breathing (SDB), sleep apnea and chronic obstructive pulmonary disease (COPD). Its major products include air flow generato …
  • Shanxi Zhendong Pharmaceutical Co Ltd (300158):製薬・医療:M&Aディール及び事業提携情報
    Summary Shanxi Zhendong Pharmaceutical Co Ltd (Zhendong Group) is a pharmaceutical company. The company researches, develops, manufactures and markets pharmaceutical products and Chinese medicines in China. It offers products such as cancer drugs, cardiovascular drugs, infectious disease drugs, resp …
  • Lanco Infratech Ltd:発電所・企業SWOT分析
    Lanco Infratech Ltd – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • CooperSurgical Inc:企業のM&A・事業提携・投資動向
    CooperSurgical Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CooperSurgical Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Wausau Paper Corporation:企業の戦略・SWOT・財務情報
    Wausau Paper Corporation - Strategy, SWOT and Corporate Finance Report Summary Wausau Paper Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Continental Resources, Inc.:企業の戦略・SWOT・財務情報
    Continental Resources, Inc. - Strategy, SWOT and Corporate Finance Report Summary Continental Resources, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Pharco Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharco Pharmaceuticals Inc (Pharco Pharmaceuticals), a subsidiary of Pharco Corp, is a manufacturer of branded and generic pharmaceutical products. The company offers products such as alambupine, alfatral, amlodipine, amrase, amrizole, bisadyl, bromhexine, carbolase, ciprofloxacin, dexametha …
  • Strategic Energy Resources Ltd (SER):石油・ガス:M&Aディール及び事業提携情報
    Summary Strategic Energy Resources Ltd (SER) is an oil and gas exploration and production company that acquires, explores, develops, and produces land prospective for oil and gas, graphite and mineral properties. The company operates its oil and gas projects in Gippsland basin in offshore Victoria. …
  • Austrian Airlines AG:企業の戦略・SWOT・財務情報
    Austrian Airlines AG - Strategy, SWOT and Corporate Finance Report Summary Austrian Airlines AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • PFB Corp (PFB):企業の財務・戦略的SWOT分析
    Summary PFB Corp (PFB) is a diversified company. The company manufactures and distributes insulating building products and technologies. The company provides EPS product solutions such as insulspan structural insulating panel systems, rating system, insulated concrete forming system, timber framing …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆